Sulphonamides Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.10 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Sulphonamides Market Analysis
The sulphonamides market is anticipated to record a CAGR of nearly 4.1% over the forecast period.
The COVID-19 pandemic had a substantial impact on the market due to supply chain disruptions and pandemic-related restrictions worldwide. However, initially, many antibiotics were used to treat COVID-19, which were widely prescribed and studied as the COVID-19 remedy. During the COVID-19 outbreak, antibiotics were used to improve public health and decrease the potential of other infectious exposures. An article published by Bioorganic & Medicinal Chemistry Letters in January 2021 stated that a novel class of cyclic sulfonamide derivatives acted as a promising new template for SARS-CoV-2 inhibitors using structural activity relationship optimization, viral inhibitory assays, cytotoxicity assays, and pharmacokinetic studies. Thus, the sulphonamides market is expected to grow due to an increasing number of studies on various sulfonamide derivatives used to treat COVID-19 infections.
Certain factors that are driving the market's growth include the increasing prevalence of chronic diseases worldwide and growing R&D activities in pharmaceutical companies. As per an article published by JEADV in March 2022, more than 94 million Europeans complain of uncomfortable skin sensations like itching, burning, or dryness. The most frequently reported conditions were fungal skin infections (8.9%), acne (5.4%), and atopic dermatitis or eczema (5.5%). Alopecia, acne, eczema, and rosacea were more common in women, whereas men were more likely to suffer from psoriasis and sexually transmitted infections (STIs). Similarly, there is a high prevalence of the diverse range of skin infections, gastrointestinal tract (GIT) infections, urinary tract infections, and respiratory tract infections globally. For instance, as per the report published by Verywell Health in November 2022, urinary tract infection (UTI) is an infection of the urinary system, which can affect the bladder (cystitis), urethra (urethritis), or kidneys (pyelonephritis), and 6 in 10 women in the United States experienced a UTI.
There has been an upsurge in the usage of advanced technologies, such as high throughput, bioinformatics, and combinatorial chemistry, for better drug candidate identification. Drug discovery has evolved significantly with emerging technologies, helping the process become more refined, accurate, and less time-consuming. However, increasing side effects associated with the use of sulfa drugs and the availability of substitute drugs may hinder the market's growth over the forecast period.
Sulphonamides Market Trends
This section covers the major market trends shaping the Sulphonamides Market according to our research experts:
Urinary Tract Infection is Expected to Witness Significant Growth During the Forecast Period
Urinary tract infection (UTI) affects the urinary tract. It is one of the most common bacterial infections. It is more common in women than men. UTI is one of the most frequent causes of morbidity and mortality, globally. The prevalence of uncomplicated UTIs is significantly higher compared to recurring, complicated UTIs.
As per the study report published by the European Journal of Medical Research in February 2022, urinary tract infections are highly prevalent in patients with type 2 diabetes. A number of research studies on aging participants showed that the prevalence of urinary tract infections in diabetic Iranian patients increased due to their growing age. Hence, the increasing prevalence of UTI due to the growing elderly population is expected to boost the demand for antimicrobials like sulphonamides and help in the market's growth over the forecast period.
With new research funding for infectious diseases, including UTIs, and the substantial availability of various sulfonamide drug formulations at a reasonable price, the prevalence of complicated UTIs is expected to increase in the future, owing to the rising drug-resistant bacteria and excessive use of antibiotics. A vast majority of physicians prescribe sulphonamides to treat UTI cases, which may also contribute to the growth of the market in the future.
North America is Expected to Register Significant Growth in the Market During the Forecast Period
North America is expected to have significant growth in the market due to growing R&D activities in medical sciences, availability of technologically advanced products, rising use of antibiotics, and the growing elderly population.
The rising incidence of tuberculosis in the region is the key factor driving the market's growth as sulphonamide is used as a potential medicine to treat drug-resistant tuberculosis. For instance, according to the CDC's NTSS, 7,860 tuberculosis cases were reported in 50 US states and the District of Columbia (DC) in 2021. The national incidence of reported tuberculosis cases (cases per 100,000 people) increased by 9.4% in 2021 (2.37) compared to the previous year. As per the same source, in 2021, some of the regions with the highest number of tuberculosis cases were California (1,750), Texas (991), Florida (499), Pennsylvania (166), Ohio (149), and Arizona (129). Thus, widespread tuberculosis in the region needs proper treatment measures, which may drive the demand for sulphonamides in the region.
In North America, the United States is expected to witness notable growth in the sulphonamide market during the forecast period due to the high prevalence and incidence of infectious diseases. According to the article by the CDC published in November 2021, the common cold affects millions of people in the United States each year. On average, adults have cold 2-3 times every year, with children being more at risk. Thus, due to the high burden of bacterial infectious diseases, the United States is expected to hold a major share of the sulphonamides market in North America.
Sulphonamides Industry Overview
The sulphonamides market is fragmented and consists of several major players. Companies like AA Pharma Inc., Abbott Laboratories, Akorn Operating Company LLC, GSK PLC, Lexine Technochem Pvt. Ltd, Viatris Inc., Pfizer Inc., Amneal Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd, and F. Hoffmann-La Roche Ltd hold a substantial share in the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new products at lesser prices.
Sulphonamides Market Leaders
-
Pfizer Inc.
-
AA Pharma Inc.
-
GSK plc
-
Viatris Inc
-
Teva Pharmaceutical Industries Ltd
*Disclaimer: Major Players sorted in no particular order
Sulphonamides Market News
- In August 2022, Valeo Pharma Inc. entered a commercialization and supply agreement with Novartis Pharmaceuticals Canada Inc. for the commercialization of SIMBRINZA (brinzolamide/brimonidine tartrate) in Canada. Brinzolamide is a sulfonamide and carbonic anhydrase inhibitor with a specific affinity for carbonic anhydrase II.
- In July 2022, Azurity Pharmaceuticals Inc. received approval from the US FDA for ZONISADE (zonisamide oral suspension). Zonisamide is a sulfonamide antiepileptic drug.
Sulphonamides Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Chronic Diseases
4.2.2 Growing R&D Activities in Pharmaceutical Companies
4.3 Market Restraints
4.3.1 Increasing Side Effects Associated with the Use of Sulfa Drugs
4.3.2 Availability of Substitute Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Route of Administration
5.1.1 Oral
5.1.2 Topical
5.1.3 Other Routes of Administration
5.2 By Application
5.2.1 Skin Infections
5.2.2 Gastro Intestinal Tract (GIT) Infection
5.2.3 Urinary Tract Infection (UTI)
5.2.4 Respiratory Tract Infection (RTI)
5.2.5 Other Applications
5.3 By Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AA Pharma Inc.
6.1.2 Abbott Laboratories
6.1.3 F. Hoffmann-La Roche Ltd
6.1.4 GSK PLC
6.1.5 Lexine Technochem Pvt. Ltd
6.1.6 Viatris Inc.
6.1.7 Pfizer Inc.
6.1.8 Teva Pharmaceutical Industries Ltd
6.1.9 Amneal Pharmaceuticals LLC
6.1.10 Akorn Operating Company LLC
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Sulphonamides Industry Segmentation
As per the scope of the report, sulfonamides refer to the sulfa-related group of antibiotics, which are used to treat bacterial infections and some fungal infections. Sulfa drugs kill bacteria and fungi by interfering with cell metabolism.
The sulphonamides market is segmented by route of administration (oral, topical, and other routes of administration), application (skin infection, gastro-intestinal tract (GIT) infection, urinary tract infection (UTI), respiratory tract infection (RTI), and other applications), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Route of Administration | |
| Oral | |
| Topical | |
| Other Routes of Administration |
| By Application | |
| Skin Infections | |
| Gastro Intestinal Tract (GIT) Infection | |
| Urinary Tract Infection (UTI) | |
| Respiratory Tract Infection (RTI) | |
| Other Applications |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Sulphonamides Market Research FAQs
What is the current Sulphonamides Market size?
The Sulphonamides Market is projected to register a CAGR of 4.10% during the forecast period (2024-2029)
Who are the key players in Sulphonamides Market?
Pfizer Inc. , AA Pharma Inc. , GSK plc, Viatris Inc and Teva Pharmaceutical Industries Ltd are the major companies operating in the Sulphonamides Market.
Which is the fastest growing region in Sulphonamides Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Sulphonamides Market?
In 2024, the North America accounts for the largest market share in Sulphonamides Market.
What years does this Sulphonamides Market cover?
The report covers the Sulphonamides Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Sulphonamides Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Infertility Drugs Industry Report
Statistics for the 2024 Infertility Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Infertility Drugs analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
